Cellectar Biosciences CLRB 深 沪
已收盘 10-31 16:00:00 美东时间
3.39
+0.130
+3.99%
华盛通- 最 高3.41
- 今 开3.26
- 成交量 6.23万股
- 最 低 3.25
- 昨 收 3.26
- 总市值 1082.09万
- 52周最高 66.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.25
- 委 比 -38.01%
- 总股本 319.20万
- 历史最高 276000.00
- 量 比 0.06
- 振 幅 4.91%
- 历史最低 3.25
- 每 手 1
- 风险率 14.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CLRB stock has given up its prior gain. Cellectar Biosciences shares were trading higher after the company received Rare Pediatric Disease designation from the FDA for Iopofosine I-131 in relapsed or refractory pediatric high-grade glioma.
CLRB stock has given up its prior gain. Cellectar Biosciences shares were tradi...
10-27 21:27
Cellectar Biosciences shares are trading higher after the company received Rare Pediatric Disease designation from the FDA for Iopofosine I-131 in relapsed or refractory pediatric high-grade glioma.
Cellectar Biosciences shares are trading higher after the company received Rare...
10-27 20:33
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
Cellectar Biosciences announced that the FDA granted Rare Pediatric Drug Designation to iopofosine I 131 for treating inoperable relapsed or refractory pediatric high-grade glioma (r/r pHGG). Interim data from the CLOVER-2 Phase 1b trial showed extended progression-free survival (PFS) and overall survival (OS), with patients experiencing disease control and reduced tumor volume. The drug demonstrated a favorable safety profile, with no severe off...
10-27 12:30
Cellectar Biosciences Presented Preclinical Data On CLR 121225, A Novel Actinium-Based Alpha-Emitter For Pancreatic Ductal Adenocarcinoma Which Has Completed IND-Enabling Studies And May Advance To A Phase 1 Trial
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief
10-14 20:37
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
Cellectar Biosciences announced promising preclinical data for CLR 225, a novel actinium-based radio conjugate targeting pancreatic ductal adenocarcinoma (PDAC). Studies showed significant tumor growth inhibition and potential survival benefits across three pancreatic cancer models. CLR 225 demonstrated safe biodistribution and linear pharmacokinetics, supporting its advancement to Phase 1 trials. The drug's ability to penetrate the dense extrace...
10-14 12:30
Cellectar Biosciences Raises $5.8M Through Warrant Exercise
Cellectar Biosciences ( ($CLRB) ) has provided an update. On October 7, 2025, C...
10-11 05:02
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
Cellectar Biosciences entered into an agreement with institutional investors to exercise existing warrants, generating approximately $5.8 million in gross proceeds. Ladenburg Thalmann & Co. acted as the placement agent. The warrants were exercised at $5.25 per share, yielding 1,048,094 new Series I and II warrants. These warrants are exercisable at $6.00 per share, with Series I expiring in five years and Series II in 18 months. Proceeds will sup...
10-07 12:30
Cellectar Eyes 2027 EU Launch As EMA Backs Conditional Approval Path For Its Blood Cancer Drug
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that after a scientific advice
10-06 19:08
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
Cellectar Biosciences announced plans to submit a Conditional Marketing Authorization (CMA) application for iopofosine I 131 to treat post-BTKi refractory Waldenstrom's macroglobulinemia (WM) in Europe, following scientific advice from the European Medicines Agency (EMA). The submission is expected in early 2026, with potential European approval and commercial launch in 2027. Iopofosine I 131, a first-in-class radioconjugate therapy, has shown an...
10-06 11:00
Evestia To Provide Cellectar With Full CRO Services For Upcoming Phase 1b Study Evaluating CLR 125 For Treatment Of Triple-Negative Breast Cancer
Cellectar Biosciences, Inc. ("Cellectar") (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Evestia Clinical ("Evestia"), a
09-24 20:34
